A Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Renally Impaired Adults With Chronic Hepatitis C Virus Genotype 1 - 6 Infection

NCT02651194 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

104

Enrollment

INDUSTRY

Sponsor class

Conditions

Chronic Hepatitis C Virus (HCV) Infection

Interventions

DRUG: ABT-493/ABT-530

Sponsor

AbbVie